Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT01165905

Public ClinicalTrials.gov record NCT01165905. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Dose Escalation Study of Gemcitabine and 24 Hour Infusion of ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors

Study identification

NCT ID: NCT01165905
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Traws Pharma, Inc.; Industry
Enrollment: 10 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

ON 01910.Na Drug
Gemcitabine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2009
Primary completion: Jun 30, 2011
Completion: Jun 30, 2011
Last update posted: Jun 22, 2017

2010 – 2011

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Department of Medicine, University of California San Francisco	San Francisco	California	94143	—
Albert Einstein Cancer Center/Montefiore Medical Center	The Bronx	New York	10461	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01165905, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 22, 2017 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01165905 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →